- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03112967
Safety and Efficacy of Low-volume Preparation in the Elderly: Oral Sulfate Solution
Safety and Efficacy of Low-volume Preparation in the Elderly: Oral Sulfate Solution vs 4L PEG Dolution
The investigators will investigate the safety and efficacy of low-volume preparation (Oral Sulfate solution) compared to 4L PEG solution in bowel preparation before colonoscopy.
One aim of this study was to investigate the efficacy of low-volume preparation (Oral Sulfate solution) on bowel preparation before colonoscopy.
Study Overview
Status
Conditions
Detailed Description
Traditionally, polyethylene glycol (PEG) solution, which requires ingestion of a large volume of liquid, has been used and now to a low-volume preparations because of its clear advantages in tolerability. The tolerability of bowel preparations is related to their volume, taste, and side effects, with this being a particular problem in the elderly. Meanwhile, a new oral sulfate solution (OSS, SUPREP, Braintree Laboratories, Braintree, Mass) formulation as an effective low-volume bowel cleansing agent, with a split-dose regimen was recently developed in 2009.
Concerned about being able to better complete ingestion of bowel cleansing agent, OSS with lower volume and improved taste features, as long as it does not sacrifice safety, shuld be a better choice than PEG. Many studies have already looked at the efficacy and safety of OSS compared to PEG in average risk population, but there are no data available in solely at the elderly population. In this context, we hypothesized that OSS could be a good alternative to a standard 4L-PEG solution in elderly patients.
In this report, we describe a multicenter, prospective, investigator-blind, randomized, controlled trial investigating OSS with 4L PEG for efficacy and safety in the elderly.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Seoul, Korea, Republic of, 05278
- Department of Internal Medicine, Kyung Hee University College of Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
All participants from 65 to 75 age
Exclusion Criteria:
- Underwent Colorectal surgery
- CHF, Acute MI <6 months
- ASA class III =<
- LC, CRF, Ascite, IBD, or Severe inflammatory state
- Severe constipation (Bowel movement 3/wk > or Taking stool softener)
- Disabled person physically or mentally
- Refuse consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: OTHER
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: OSS(Suprep)
Oral Sulfate solution (Suprep) in day before and split-dose regimens In the OSS arm: between 17:00 and 18:00 hours on the day before colonoscopy, subjects were instructed to pour one 180-ml bottle of the study medication into a provided 480-ml mixing cup and fill it with water and then drink the entire volume, followed by two additional 480 ml of water.
At approximately 6:00 a.m. on the following morning, the subjects took the second dose of OSS by same formulation protocol.
|
Oral Sulfate solution (Suprep) in day before and split-dose regimens In the OSS arm: between 17:00 and 18:00 hours on the day before colonoscopy, subjects were instructed to pour one 180-ml bottle of the study medication into a provided 480-ml mixing cup and fill it with water and then drink the entire volume, followed by two additional 480 ml of water.
At approximately 6:00 a.m. on the following morning, the subjects took the second dose of OSS by same formulation protocol.
Other Names:
|
ACTIVE_COMPARATOR: 4L PEG solution(Colyte)
4L PEG solution in day before and split-dose regimens In the 4L PEG arm: subjects had the first 2L between 18:00 and 19:00 hours (250mL every 15 minutes) in the evening before the colonoscopy.
And the second 2L was given between 07:00 and 08:00 on the day of colonoscopy.
|
4L PEG solution in day before and split-dose regimens In the 4L PEG arm: subjects had the first 2L between 18:00 and 19:00 hours (250mL every 15 minutes) in the evening before the colonoscopy.
And the second 2L was given between 07:00 and 08:00 on the day of colonoscopy.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Efficacy in bowel preparation
Time Frame: Up to 2 months
|
The boston bowel preparation scale The BBPS uses a 10-point (0-9) summation scale assessing bowel preparation quality, by a 3 point scoring system of 0 to 3 in 3 segments of the colon (right colon, transverse colon, and left colon), where 0 = ''unprepared colon with mucosa not seen because of solid stool,'' 1 = ''portion of colonic mucosa of the segment seen, but other areas not well seen due to staining, residual stool, and/or opaque liquid,'' 2 = ''minor amount of residual staining, stool, and/or opaque liquid, but colonic mucosa of the segment seen well,'' and 3 = ''entire colonic mucosa seen well with no residual staining, stool or opaque liquid.''
An adequate bowel preparation was defined by a total BBPS score ≥ 6 with all segment scores ≥ 2, and excellent cleansing was considered as a score of > 7.
|
Up to 2 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse events
Time Frame: Up to 2 months
|
Proportion of adverse events. Adverse events recorded on the questionnaires included nausea, vomiting, abdominal pain, bloating, sleep disturbance, numbness, weakness/faint feeling, fecal incontinence, and thirsty. Blood samples were taken at the screening visit and the day of the procedure and were analysed for serum electrolytes (sodium, potassium, chloride, calcium, phosphate and magnesium), blood urea nitrogen (BUN), creatinine and glomerular filtration rate (GFR). Incident kidney injury was defined as a 25% increase in serum creatinine levels or longitudinal significant change in estimated glomerular filtration rate. |
Up to 2 months
|
compliance and acceptability
Time Frame: Up to 2 months
|
proportion of patients willingness
|
Up to 2 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Min Seob Kwak, MD,PhD, Kyunghee University Hospital at Gangdong
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 2016-03-021
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bowel Preparation
-
University of British ColumbiaCompletedEfficacy of Bowel Preparation | Ease of Bowel Preparation and Patient TolerabilityCanada
-
Alexandra Hospital, Athens, GreeceRecruitingBowel Preparation | Preparation for ColonoscopyGreece
-
Inje UniversityUnknownBOWEL PREPARATION (BOWEL CLEANSING)Korea, Republic of
-
Jinling Hospital, ChinaRecruiting
-
Ferring PharmaceuticalsRecruitingBowel PreparationUnited States
-
Taejoon Pharmaceutical Co., Ltd.Completed
-
Azienda USL ModenaCompleted
-
Shandong UniversityUnknownBowel PreparationChina
-
Samsung Medical CenterCompletedBowel PreparationKorea, Republic of
Clinical Trials on low-volume preparation, oral sulfate solution
-
Shandong UniversityUnknown
-
Tel-Aviv Sourasky Medical CenterCompletedHemorrhage | Vomiting | Morbid Obesity | Intra-Abdominal Abscess | Acidosis | RefluxIsrael
-
Azienda USL ModenaCompleted
-
Centre Hospitalier Universitaire de BesanconCompletedPatient With an Indication of Colonoscopy for Inflammatory Bowel DiseaseFrance
-
Valduce HospitalIstituti Ospitalieri di Cremona; Istituto Clinico Humanitas; Nuovo Regina Margherita...UnknownColonic AdenomasItaly
-
Nutricia UK LtdCompletedMalnutritionUnited Kingdom
-
Bo-In LeePharmbio Korea Co., Ltd.CompletedCathartic ColonKorea, Republic of
-
National Cancer Center, KoreaSeoul National University Hospital; Seoul National University Bundang Hospital and other collaboratorsUnknown
-
Roxane LaboratoriesCompleted
-
National Cancer Center, KoreaDaehang HospitalCompletedComparison of Polyethylene Glycol With Ascorbic Acid and Oral Sulfate Solution for Bowel PreparationHealthyKorea, Republic of